Company - iData Insights - ReDiscovering Data | Research Reports, News, Events, Research on Demand

Sectors


Price








Published







Company Reports Titles

  • First Electric Cooperative Corporation - Strategic SWOT Analysis Review

    First Electric Cooperative Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  GlobalData s summarization of the company s business strategy. - SWOT analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list of key locations and subsidiaries of the company, including contact details. Highlights First Electric Cooperative Corporation (FEC) is a not-for-profit electric cooperative that undertakes transmission and distribution of electricity to residential, commercial and industrial, agricultural, and public authorities in Arkansas. It purchases power from independent power producers and distributes through its substations and large network of transmission lines. The cooperative operates through its regional offices in Jacksonville, Benton, Heber Springs, Perryville and Stuttgart. FEC is headquartered in Jacksonville, Arkansas, the US. First Electric Cooperative Corporation Key Recent Developments Feb 09, 2016: First Electric Cooperative of Jacksonville adds solar with Today s Power, Inc. Jul 02, 2015: First Electric members re-elect Hudspeth Jan 08, 2015: First Electric Cooperative Provides Real-Time Alerts and Restoration Status Updates to Members With TextPower Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report s analysis of the company s business structure, operations, major products and services and business strategy. - Understand and respond to your competitors business structure and strategies with GlobalData s detailed SWOT analysis. In this, the company s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company. - Examine potential investment and acquisition targets with this report s detailed insight into the company s strategic, business and operational performance. Note: Some sections may be missing if data is unavailable for the company.

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Bristol-Myers Squibb Company (BMY) - Financial and Strategic SWOT Analysis Review

    Bristol-Myers Squibb Company (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company, which focuses on innovative drugs to address unmet medical needs of patients with serious diseases. It discovers, develops, licenses, manufactures, markets and distributes biopharmaceuticals and related healthcare products. Its product line includes chemically-synthesized drugs and biological products in the areas of cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis. The company offers its products across the world through a network of wholesalers, retail pharmacies, hospitals and government entities. BMS has research and development facilities in the US, Belgium, England, France and Japan; and has manufacturing facilities in Puerto Rico, the US, France, Italy, Ireland, Japan, Mexico and China. BMS is headquartered in New York, the US. Bristol-Myers Squibb Company Key Recent Developments Jul 28, 2016: Bristol-Myers Squibb Reports Second Quarter Financial Results Jul 25, 2016: Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head Jul 18, 2016: Publication of HPTN 052 final results Jul 01, 2016: Major Biopharmaceutical Signs up to a MedAdvisor Patient Engagement Program Jun 21, 2016: BMS and Biogen to Give Biomanufacturing Keynote Presentations at CHI's Eighth Annual The Bioprocessing Summit Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Biogen Inc (Biogen) is a global biotechnology company that discovers, develops, manufactures and commercializes therapies for treating neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company s marketed product portfolio includes Avonex, Tysabri, Tecfidera, Fampyra, and Plegridy for the treatment of multiple sclerosis (MS); Eloctate for hemophilia A; Alprolix for hemophilia B and Fumaderm (fumaric acid esters) for plaque psoriasis. Through its joint venture company, Samsung Bioepis the company also develops, manufactures and markets biosimilars. The company also has several products in its developmental pipeline targeting various indications namely MS, hemophilia and other neurodegenerative diseases. The company markets its products in the US, several European countries and Japan through its own sales forces and marketing groups. Biogen is headquartered in Cambridge, Massachusetts, the US. Biogen Inc Key Recent Developments Aug 09, 2016: Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company Jul 22, 2016: Medidata Cloud Technology Selected to Support Biogen Clinical Trials Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion Jun 28, 2016: Biogen Selects Cognizant's SmartTrials Platform Jun 21, 2016: Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review

    Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Biocon Limited (Biocon) is a global biopharmaceutical company specialized in biopharmaceuticals and research services. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations and biologicals. Its core therapeutic areas include anti-diabetics, cardiovascular, anti-inflammatory, anti-obesity, hepato-protective and gastro-intestinal drugs, nutraceuticals, digestive-aid enzymes, immunosuppressants and anti-oxidants. The company offers branded formulations in the fields of cardiology, diabetology, oncology, immunotherapy, nephrology and comprehensive care. The company also provides licensing, contract manufacturing and research services to biotechnology and pharmaceutical companies. It delivers research and development solutions to partners and customers across the world. Biocon is headquartered in Bangalore, Karnataka, India. Biocon Limited Key Recent Developments Jul 21, 2016: Biocon Reports a Strong Q1 FY17 Revenues at Rs. 952 Crore, Up by 11%; EBITDA Up 15% to Rs. 271 Crore; Net Profit Up 17% at Rs. 147 Crore Apr 26, 2016: Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17% Apr 26, 2016: Biocon : Q4FY16 Net Profit at Rs 361 Cr; Revenue Crosses Rs 1,000 Cr; Up 17% Jan 22, 2016: Biocon Announces Q3 results for the quarter ended December 31, 2015 Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10% Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review

    ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights ImmunoGen, Inc. (ImmunoGen) is a biotechnology company that carries out the development of anticancer therapeutics. The company uses its proprietary antibody-drug conjugates (ADC) technology for the development of the products. It develops products for the treatment of various types of cancer including ovarian cancer, solid tumors, endometrial cancer, multiple myeloma, glioblastoma, breast, and bladder cancer. ImmunoGen also licenses its ADC technology to its partner pharmaceutical companies to develop anticancer compounds such as Kadcyla and other ADC compounds. The company focuses its research on evaluation of new targets, new antibodies, linkers and cytotoxic agents, advancement of internal product candidates through clinical trials, and others. ImmunoGen is headquartered in Waltham, Massachusetts, the US. ImmunoGen, Inc. Key Recent Developments Aug 09, 2016: ImmunoGen Announces Departure of Chief Development Officer Aug 04, 2016: ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update Apr 29, 2016: ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update Apr 26, 2016: ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer Apr 05, 2016: Daniel Junius to Retire as President and CEO of ImmunoGen Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Les Laboratoires Servier SAS - Strategic SWOT Analysis Review

    Les Laboratoires Servier SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  GlobalData s summarization of the company s business strategy. - SWOT analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list of key locations and subsidiaries of the company, including contact details. - Key manufacturing facilities  A list of key manufacturing facilities of the company. Highlights Les Laboratoires Servier SAS (Servier) is a pharmaceutical company that carries out research and development, manufacture and marketing of drugs for the treatment of cardiovascular diseases, central nervous system (CNS) diseases, diabetes, cancer and bone, muscle and joint diseases. The company's portfolio of marketed products covers various diseases including cardiovascular disease, rheumatic problems, venous disease, neurological conditions, cancer and endocrine disorders. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) across the world. With strong presence in international markets, the company sells its products across the world. Servier is headquartered in Suresnes, France. Les Laboratoires Servier SAS Key Recent Developments Jul 19, 2016: Vernalis achieves a milestone in its Oncology Collaboration with Servier Nov 26, 2015: Servier Group reorganizes its medical sales network in France Oct 05, 2015: Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners Aug 06, 2015: SERVIER Research Grant in Hypertension: the winner is Dr S?bastien Foulquier Jul 08, 2015: Cellectis Reaches Milestone in Servier Collaboration Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report s analysis of the company s business structure, operations, major products and services and business strategy. - Understand and respond to your competitors business structure and strategies with GlobalData s detailed SWOT analysis. In this, the company s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company. - Examine potential investment and acquisition targets with this report s detailed insight into the company s strategic, business and operational performance. Note: Some sections may be missing if data is unavailable for the company.

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Incyte Corporation (INCY) - Financial and Strategic SWOT Analysis Review

    Incyte Corporation (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Incyte Corporation (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. The company operates in Switzerland, France, Germany, Italy, Spain, and Luxembourg. Incyte is headquartered in Wilmington, Delaware, the US. Incyte Corporation Key Recent Developments Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs Apr 15, 2016: Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Ionis Pharmaceuticals, Inc. (IONS) - Financial and Strategic SWOT Analysis Review

    Ionis Pharmaceuticals, Inc. (IONS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Ionis Pharmaceuticals, Inc. (Ionis) formerly ISIS Pharmaceuticals, Inc. is clinical stage biopharmaceutical company which focuses on the discovery and development of RNA-targeted drugs. The company focuses on developing first in-class medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. The company develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA). The company operates through its wholly owned subsidiary, Akcea Therapeutics. Ionis is headquartered in Carlsbad, California, the US. Ionis Pharmaceuticals, Inc. Key Recent Developments Aug 09, 2016: Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016 Jul 12, 2016: Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities May 23, 2016: Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics May 04, 2016: Ionis Reports Financial Results and Highlights for First Quarter 2016 Apr 15, 2016: Ionis Pharmaceuticals Highlights Antisense Drugs to Treat Neurological Diseases at the AAN Meeting Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review

    Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases, cancer and HIV/AIDS. Gilead operates through more than 40 marketing subsidiaries in the in Europe, North America, South America, Asia-Pacific, the Middle East, Africa and Australia. The company enters into partnerships with organizations in science, academia and business to develop innovative medicines. It continues to add to its existing portfolio of products through internal discovery and clinical development programs; and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US. Gilead Sciences, Inc. Key Recent Developments Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences Board of Directors Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science s Massive Offshore Tax Dodging Aug 04, 2016: Tata Trusts and Gilead sign memorandum of understanding to address viral hepatitis in India Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF

  • Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review

    Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description  A detailed description of the company s operations and business divisions. - Corporate strategy  Analyst s summarization of the company s business strategy. - SWOT Analysis  A detailed analysis of the company s strengths, weakness, opportunities and threats. - Company history  Progression of key events associated with the company. - Major products and services  A list of major products, services and brands of the company. - Key competitors  A list of key competitors to the company. - Key employees  A list of the key executives of the company. - Executive biographies  A brief summary of the executives employment history. - Key operational heads  A list of personnel heading key departments/functions. - Important locations and subsidiaries  A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities  A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years  The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods  The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Myriad Genetics, Inc. (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company s product portfolio includes molecular diagnostic testing products that are designed to analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its own sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US. Myriad Genetics, Inc. Key Recent Developments Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results May 19, 2016: Myriad Genetics' Statement on HIPAA Complaint from Four Patients May 18, 2016: Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information May 03, 2016: Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results Mar 21, 2016: Myriad Genetics Teams Up with Access Health to Educate the Public about Hereditary Cancer and Genetic Testing Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company

    • Release Date: September 13, 2016
    • Price: USD 125
    • Format: PDF


Create Account



Log In Your Account